W. Schroeder

1.1k total citations
18 papers, 651 citations indexed

About

W. Schroeder is a scholar working on Reproductive Medicine, Surgery and Molecular Biology. According to data from OpenAlex, W. Schroeder has authored 18 papers receiving a total of 651 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Reproductive Medicine, 8 papers in Surgery and 4 papers in Molecular Biology. Recurrent topics in W. Schroeder's work include Ovarian cancer diagnosis and treatment (15 papers), Intraperitoneal and Appendiceal Malignancies (8 papers) and Angiogenesis and VEGF in Cancer (3 papers). W. Schroeder is often cited by papers focused on Ovarian cancer diagnosis and treatment (15 papers), Intraperitoneal and Appendiceal Malignancies (8 papers) and Angiogenesis and VEGF in Cancer (3 papers). W. Schroeder collaborates with scholars based in Germany, Switzerland and Australia. W. Schroeder's co-authors include Andreas du Bois, Barbara Richter, Uwe Wagner, Finlay Macrae, Prithi S. Bhathal, Hans-Joachim Lueck, Werner Meier, Jo Armes, Rainer Kimmig and Jacobus Pfisterer and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

W. Schroeder

18 papers receiving 629 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
W. Schroeder Germany	11	476	294	205	156	90	18	651
Elly Brockbank United Kingdom	13	415 0.9×	194 0.7×	337 1.6×	196 1.3×	91 1.0×	24	692
Ernst Simonsen Sweden	14	499 1.0×	271 0.9×	457 2.2×	108 0.7×	129 1.4×	24	791
Fred T. Given United States	13	458 1.0×	297 1.0×	516 2.5×	112 0.7×	106 1.2×	24	893
Ricardo Sáinz de la Cuesta Spain	12	587 1.2×	125 0.4×	358 1.7×	114 0.7×	48 0.5×	23	831
H. Pickel Austria	14	359 0.8×	217 0.7×	292 1.4×	121 0.8×	159 1.8×	52	657
Fredric V. Price United States	15	342 0.7×	99 0.3×	377 1.8×	162 1.0×	51 0.6×	32	677
U. Metzger France	14	267 0.6×	282 1.0×	227 1.1×	76 0.5×	73 0.8×	46	658
Mauro Melpignano Italy	17	647 1.4×	265 0.9×	645 3.1×	132 0.8×	179 2.0×	34	966
Jonathan Herod United Kingdom	7	1.0k 2.1×	623 2.1×	576 2.8×	232 1.5×	45 0.5×	8	1.2k
T. Latief United Kingdom	12	173 0.4×	326 1.1×	156 0.8×	160 1.0×	54 0.6×	14	529

Countries citing papers authored by W. Schroeder

Since Specialization

Citations

This map shows the geographic impact of W. Schroeder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Schroeder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Schroeder more than expected).

Fields of papers citing papers by W. Schroeder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Schroeder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Schroeder. The network helps show where W. Schroeder may publish in the future.

Co-authorship network of co-authors of W. Schroeder

This figure shows the co-authorship network connecting the top 25 collaborators of W. Schroeder. A scholar is included among the top collaborators of W. Schroeder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Schroeder. W. Schroeder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Kommoss, Stefan, Florian Heitz, Lina María Serna-Higuita, et al.. (2021). 782 Survival in advanced-stage ovarian carcinoma with high VEGF-A expression after addition of bevacizumab. Results from the German ICON7 patient cohort. A274.1–A274. 1 indexed citations

Kommoss, Stefan, Florian Heitz, Boris Winterhoff, et al.. (2018). Significant overall survival improvement in proliferative subtype ovarian cancer patients receiving bevacizumab.. Journal of Clinical Oncology. 36(15_suppl). 5520–5520. 1 indexed citations

Emons, Guenter, Christian Kurzeder, Barbara Schmalfeldt, et al.. (2014). Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: A multicenter phase II trial of the AGO Study Group (AGO-GYN 8).. Journal of Clinical Oncology. 32(15_suppl). 5565–5565. 2 indexed citations

Perren, Timothy, W. Schroeder, Éric Pujade-Lauraine, et al.. (2013). ICON7: Final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. UCL Discovery (University College London). 21 indexed citations

Gregorio, Nikolaus de, Klaus Baumann, Mignon-Denise Keyver-Paik, et al.. (2012). Outcome of patients with borderline ovarian tumors: Results of the multicenter AGO ROBOT study.. Journal of Clinical Oncology. 30(15_suppl). 5005–5005. 5 indexed citations

Canzler, Ulrich, Hans-Joachim Lueck, Werner Meier, et al.. (2011). Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors: A phase II trial of the AGO study group.. Journal of Clinical Oncology. 29(15_suppl). 5093–5093. 5 indexed citations

Sehouli, Jalid, Dirk Stengel, Philipp Harter, et al.. (2010). Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. Journal of Clinical Oncology. 29(2). 242–248. 76 indexed citations

Harter, P, Maik Hahmann, Hans-Joachim Lueck, et al.. (2009). Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis: Exploratory Analysis of the DESKTOP I Trial About Risk Factors, Surgical Implications, and Prognostic Value of Peritoneal Carcinomatosis. Annals of Surgical Oncology. 16(5). 1324–1330. 93 indexed citations

Rudlowski, Christian, et al.. (2006). Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. International Journal of Gynecological Cancer. 16(S1). 183–189. 61 indexed citations

10.

Bois, Andreas du, B. Weber, Justine Rochon, et al.. (2006). Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Journal of Clinical Oncology. 24(7). 1127–1135. 137 indexed citations

11.

12.

Bois, Andreas du, Antje Belau, Uwe Wagner, et al.. (2004). A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC–IV (AGO-OVAR protocol OVAR-8). Gynecologic Oncology. 96(2). 444–451. 22 indexed citations

13.

Bois, Andreas du, M. Combe, Justine Rochon, et al.. (2004). Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB–IV. An AGO-GINECO Intergroup phase III trial. Journal of Clinical Oncology. 22(14_suppl). 5007–5007. 13 indexed citations

14.

Bois, Andreas du, Werner Meier, Hans‐Joachim Lück, et al.. (2002). Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Annals of Oncology. 13(2). 251–257. 41 indexed citations

15.

Bois, Andreas du, Jacobus Pfisterer, W. Schroeder, et al.. (2001). Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer – a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group. Annals of Oncology. 12(8). 1115–1120. 56 indexed citations

16.

Bois, Andreas du, Hans-Joachim Lueck, Werner Meier, et al.. (2001). Cisplatin/paclitaxel vs. carboplatin/paclitaxel in 798 patients with ovarian cancer FIGO IIB-IV — Randomized phase III study the AGO (Arbeitsgemeinschaft Gynaekologische Onkologie) study group (OVAR-3 trial). European Journal of Cancer. 37. S325–S325. 5 indexed citations

17.

Schroeder, W., et al.. (1997). Predictive value of a single CTG, ultrasound and Doppler examination to diagnose acute and chronic placental insufficiency in multiple pregnancies. Journal of Perinatal Medicine. 25(4). 325–332. 4 indexed citations

18.

Armes, Jo, et al.. (1992). Collagenous colitis: jejunal and colorectal pathology.. Journal of Clinical Pathology. 45(9). 784–787. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact